As to finger pointing, given the market seems to be in a recovering mode this morning (all my biotechs are up cept fur GERN :( Yellen's loud comments on Tuesday may have been the excuse used to tear down GERN's SP by 20%, it seems more likely that the Jakafi lobby is behind all this SP manipulation. They could easily be working with some market funds and are obviously paying shills in the MPN's forum to edit out any relevant info on IMET. Who knows who they may have paid off within the FDA. The MAYO can only go so far with their partial clinical hold being lifted.
down 15% in 3 days. IBB down 4% in same time frame. This must be manipulated by hedge fund shorts. No news is usually good news.
Hedge funds made a killing again.
Wonder where are all the ambulance chasers are seeing how GERN is on the Gerney, AGAIN?
They need to launch a class action against the FDA for this frivolous hold on IMET. Enough is enough.
Irish what happened to your last post on the "Promedior PRM-151 thread"? I never read it but your handle name stayed up.
Was worried some INCY hit man may have gotten to you.
I agree with your observations but it was also the MM's fake head on Tuesday morning with the $3.09 SP, 937.700 volume spike between 9:39-9:49AM that set us up for the shorting fiesta frenzy that has followed.
He can't be shorting his own company but nothing stopping hedge funds from shorting based on likely time lines.
Upside Target Price: 4.09 Profit: 47.7% , Profit/Loss Ratio: 7.3 : 1 - Excellent for an extreme rally
Downside Target Price: 1.91 Profit: 31% , Profit/Loss Ratio: 3.4 : 1 - Good for an extreme pullback
Given the last two days of yellen bearish sentiment, odds favour upside trading 5:3. Place ur bets.
The company is obviously in a quiet period. The MM is aware that no news is pending in the short term and has taken full advantage of the recent bearish sentiment by further shorting the SP. Tuesday's open SP spike of $3.09 was made on a large million share volume followed by a smaller volume takedown throughout the day as investors responded to the fed's cautionary warning and stopped buying. Any shorting would have a major impact on SP in this climate and GERN's was one of many sitting ducks on the pond.
According to Yellen many biotechs specifically are stretched. GERN has bee hammered by a needless clinical hold which given MC LFT reversibility data submission has been already partially lifted. The downside here is limited, the upside is much greater. Yellen needs to exempt GERN from her stretched basket comment of basket case bios. We should all sign a petition and send it to the federal chairman's office. " Yellen, stop the selling and leave the market calls to Cramer."
Promedior PRM-151; recent clinical data in myelofibrosis demonstrated the potential of this immuno-oncology approach in fibrotic cancers. To quote the principal investigator of this trial " “The improvements seen in patients who have either progressed on JAK inhibitors or were deriving no further benefit from ruxolitinib speaks to the need for new therapies that target fundamental mechanisms of the disease.”
In other words there is a need for other 'effective' novel therapies. IMET has shown CR and CI for patients with 3rd & 4th stage MF, no ruxolitinib required.
Ruben Mesa, MD (Mayo Clinic, Scottsdale) is also involved with their phase II studies.
Bearish Evening Star today. That yellen has reversed the market smellen sentiment. Fed up with the Feds!
....ah the old Jun-12-2014 2.77 to 3.05 gap fill. U would have to bring that up now. We'll the MM has spoken $2.77 it is.
And here I thought GERN had too much gong fur it to be taken down below $3 again 8=3(
All because of yellen at gaps.